CUVITRU: payments to doctors
Payments that named CUVITRU as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2M
- Providers
- 6,817
- Transactions
- 39,362
- Average per transaction
- $51
The per-transaction average — $51 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,817 providers the average total is $296, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,898,077 | 94.2% |
| Shire North American Group Inc | $117,590 | 5.8% |